Vimta Labs Limited (VIMTALABS)

Loading page…

Vimta Labs Limited (VIMTALABS) · mywealthgrid

About

Vimta Labs provides healthcare research, analytics and technology services, operating at a quarterly revenue scale of ₹100–109 Crore and generating ₹18–21 Crore in quarterly net profit. The company is positioned with stable 34–37% operating margins and an exceptionally low debt load (D/E 0.06), commanding a market cap of ₹2,757.99 Crore.

Face value: ₹2

Market cap

₹2,612 Cr

P/E

42.6×

P/B

8.2×

Dividend yield

0.3%

ROE

13.6%

ROCE

17.4%

Debt / equity

0.06

OPM

27.3%

EPS (TTM)

₹13.7

Book value

₹71.5

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

High valuation multiple (PE 44.93) against modest ROE (13.64%) — verify if earnings growth justifies the valuation or if the market is overpricing relative to historical returns
Stock declined 4.97% over one year despite 15.5% revenue growth (Mar 2025 to Jun 2026) and 14.8% net profit growth — verify what explains the disconnect: sector headwinds, valuation reset, or concerns not captured in reported P&L
Extreme 52-week stock volatility (130% range: ₹380.7–₹877.2) — verify what drives the swings and whether they reflect cyclical demand, market mispricing, or operational unpredictability
Quarterly revenue has been lumpy (declined from ₹109.25 Cr in Mar 2026 to ₹109.07 Cr in Jun 2026, prior dip to ₹98.63 Cr in Dec 2025) — verify if growth is sustainable or subject to seasonal/cyclical compression

Generated analysis · source review pending

Growth drivers

Revenue grown 15.5% from Mar 2025 to Jun 2026 (₹94.44 Cr to ₹109.07 Cr), indicating traction in core services — verify which service lines drive expansion and if growth is sustainable
Net profit growth (14.8% over same period, ₹18.32 Cr to ₹21.04 Cr) has outpaced revenue growth, suggesting stable cost management — verify if expense discipline is durable as the company scales
Exceptionally low leverage (D/E 0.06) and consistent cash generation (regular dividends and 2025-06-13 bonus) — verify management's strategy for deploying balance-sheet capacity to fund growth
Operating margins sustained at 34–37% across trailing quarters, indicating consistent pricing or operational control — verify if this discipline can be maintained as volume and customer mix evolve

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹584.4-1.2%1Y

Quick read

rule-based

Pros

+High return on capital employed of 21.9%
+Healthy operating margin of 27.3%
+Profit CAGR of 24.2% over the last 3 years
+Almost debt-free (debt/equity 0.1)
+Comfortable interest coverage of 26.7×

Cons

−Trading at 8.2× book value

Research score

Structured signal from quality, growth, valuation and momentum.

57/100

Business quality: 69
Growth: 72
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
	181	211	278	318	318
COGS	54	61	79	74	76
Gross profit	127	150	199	244	242
	97	97	119	149	155
	30	53	80	95	87
OPM %	16.6%	25.1%	28.9%	29.8%	27.3%
Depreciation	21	23	23	31	34
Interest	4	2	2	3	2
	3	1	0	3	4
Profit before tax	8	29	56	65	54
Tax	1	7	14	17	13
Tax %	17.3%	25%	25.8%	25.9%	24.7%
	7	21	41	48	41
PAT margin %	3.8%	10.2%	14.9%	15.1%	12.9%
EPS (₹)	3.1	9.7	18.7	21.8	18.5
EPS adjusted (₹)	1.6	4.8	9.4	10.9	9.3
	0%	20.7%	10.7%	9.2%	10.8%
Annual report	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Equity capital	4	4	4	4	4
Reserves	168	190	230	277	315
Minority interest	—	—	—	—	0
	23	30	19	15	19
	50	50	54	66	61
Total equity & liabilities	246	274	307	362	400
	138	135	169	175	171
CWIP	—	17	0	12	59
Investments	—	0	0	0	0
	108	122	138	175	170
Total assets	246	274	307	362	400

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
	24	37	59	88	61
	-21	-32	-38	-57	-76
	-1	-5	-17	-11	-2
Net cash flow	3	1	5	20	-17
Free cash flow	—	4	29	40	-15
CFO / Operating profit %	81.3%	70.2%	73.6%	92.7%	70.2%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Margins
Gross margin %	70.3%	71%	71.5%	76.8%	76%
EBITDA margin %	16.6%	25.1%	28.9%	29.8%	27.3%
EBIT margin %	5%	14.2%	20.5%	20.2%	16.5%
PAT margin %	3.8%	10.2%	14.9%	15.1%	12.9%
Working capital
Receivable days	117	127	101	92	100
Inventory days	116	87	80	112	118
Payable days	—	89	57	71	39
NWC days	—	126	124	132	179
Leverage
Current ratio	1.67	2.05	2.6	2.86	2.91
Debt to EBITDA	0.77	0.57	0.24	0.16	0.22
Debt to equity	0.13	0.16	0.08	0.05	0.06
Interest coverage	3.2	14.2	38.9	25.5	26.7
Asset turnover	0.74	0.77	0.91	0.88	0.8
Return ratios
Return on assets %	2.8%	7.8%	13.5%	13.3%	10.3%
Return on capital employed %	6.4%	15%	24.3%	24%	17.4%
Return on equity %	4%	11%	17.7%	17.1%	12.8%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	37.01%	36.98%	36.92%	36.89%	36.89%	36.76%	36.7%	36.67%	35.99%	35.9%	35.85%	35.67%
	2.74%	2.88%	5.13%	5.16%	3.31%	3.81%	3.66%	3.49%	4.33%	4.59%	4.89%	4.42%
	1.5%	1.49%	1.5%	1.49%	0%	1.16%	1.43%	1.42%	0.87%	0.11%	0.14%	0.37%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	58.75%	58.65%	56.45%	56.46%	59.8%	58.27%	58.21%	58.42%	58.81%	59.4%	59.12%	59.54%
No. of shareholders	—	—	—	—	—	—	—	—	55,933	54,467	51,623	50,190

Promoter holding down 1.34 percentage points since Sep 2023.

215 deals · 29 Aug 2024 – 21 Jul 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
21 Jul 2026	MICROCURVES TRADING PRIVATE LIMITED	Bulk	NSE	Sell	3,66,347	₹604.27	₹22.14 Cr
21 Jul 2026	MICROCURVES TRADING PRIVATE LIMITED	Bulk	NSE	Buy	3,66,347	₹603.90	₹22.12 Cr
25 Sept 2025	HRTI PRIVATE LIMITED	Bulk	NSE	Buy	2,95,059	₹753.57	₹22.23 Cr
25 Sept 2025	HRTI PRIVATE LIMITED	Bulk	NSE	Sell	2,94,330	₹755.68	₹22.24 Cr
19 Sept 2025	HRTI PRIVATE LIMITED	Bulk	NSE	Sell	3,93,620	₹822.81	₹32.39 Cr
19 Sept 2025	HRTI PRIVATE LIMITED	Bulk	NSE	Buy	3,76,745	₹821.31	₹30.94 Cr
19 Sept 2025	SPDR PORTFOLIO EMERGING MARKETS ETF	Bulk	NSE	Buy	3,46,373	₹824.05	₹28.54 Cr
19 Sept 2025	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	2,48,631	₹821.32	₹20.42 Cr
19 Sept 2025	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	2,48,631	₹821.90	₹20.43 Cr
11 Sept 2025	HRTI PRIVATE LIMITED	Bulk	NSE	Buy	2,60,682	₹799.62	₹20.84 Cr

1–10 of 215

1 / 22

Mr. Sivalinga Prasad VasireddiExecutive Director-Chairperson
Mrs. Harita VasireddiExecutive Director-MD
Mr. Harriman VungalExecutive Director
Mr. Satya Sreenivas NeerukondaExecutive Director
Mrs. Prameela Rani YalamanchiliNon-Executive - Independent Director
Mr. Gutta Purnachandra RaoNon-Executive - Independent Director
Mr. Sanjay DaveNon-Executive - Independent Director
Mr. Yadagiri R PendriNon-Executive - Independent Director
Mr. Siva Rama Krishna KambhampatiChief Financial Officer
Mrs. Sujani VasireddiCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 1 fund houses

Held by these funds

of the company's equity

All mutual funds

0.2%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

1 schemes

		Shares
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	417	0.03	0.06%	0.001%	+1

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Jul 2026Transcript AI Summary PPT REC
May 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

17

Final dividend18 Jun 2026 · ex-date₹2
Dividend dividend30 May 2025 · ex-date₹2
Final dividend11 Jul 2024 · ex-date₹2
Final dividend21 Jun 2023 · ex-date₹2
Dividend dividend16 Jun 2022 · ex-date₹2
Dividend dividend25 Jun 2021 · ex-date₹2
Dividend dividend18 Jul 2019 · ex-date₹2
Dividend dividend14 Aug 2018 · ex-date₹2
Dividend dividend25 Aug 2016 · ex-date₹1
Dividend dividend6 Aug 2015 · ex-date₹1
Dividend dividend27 Jun 2014 · ex-date₹2
Dividend dividend23 May 2013 · ex-date₹0.6
Dividend dividend15 Sept 2011 · ex-date₹0.4
Dividend dividend23 Sept 2010 · ex-date₹0.8
Dividend dividend10 Sept 2009 · ex-date₹0.8
Dividend dividend28 Aug 2008 · ex-date₹0.8
Dividend dividend2 Aug 2007 · ex-date₹0.8

1

Board meeting to consider results20 Jul 2026

1

Bonus 1:113 Jun 2025 · ex-date

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

22 announcementsExport CSV

30 Sept 2026, 11:39 amInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

Loading announcements…

Ratio	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Margins
Gross margin %	70.3%	71%	71.5%	76.8%	76%
EBITDA margin %	16.6%	25.1%	28.9%	29.8%	27.3%
EBIT margin %	5%	14.2%	20.5%	20.2%	16.5%
PAT margin %	3.8%	10.2%	14.9%	15.1%	12.9%
Working capital
Receivable days	117	127	101	92	100
Inventory days	116	87	80	112	118
Payable days	—	89	57	71	39
NWC days	—	126	124	132	179
Leverage
Current ratio	1.67	2.05	2.6	2.86	2.91
Debt to EBITDA	0.77	0.57	0.24	0.16	0.22
Debt to equity	0.13	0.16	0.08	0.05	0.06
Interest coverage	3.2	14.2	38.9	25.5	26.7
Asset turnover	0.74	0.77	0.91	0.88	0.8
Return ratios
Return on assets %	2.8%	7.8%	13.5%	13.3%	10.3%
Return on capital employed %	6.4%	15%	24.3%	24%	17.4%
Return on equity %	4%	11%	17.7%	17.1%	12.8%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Syngene International LimitedSYNGENESYNGENE	₹14,586 Cr	₹14,595 Cr	₹3,600 Cr	₹803 Cr	24.6%	₹221 Cr	8.5%	9.8%	6.6%	-32
Indegene LimitedINDGNINDGN	₹14,303 Cr	₹14,303 Cr	₹3,813 Cr	₹638 Cr	17.6%	₹401 Cr	11.4%	17.9%	13.9%	79
Suven Life Sciences LimitedSUVENSUVEN	₹8,139 Cr	₹8,139 Cr	₹9 Cr	₹-366 Cr	—	₹-352 Cr	—	-78.4%	-78.8%	72
Vimta Labs LimitedVIMTALABSVIMTALABS	₹2,612 Cr	₹2,631 Cr	₹336 Cr	₹112 Cr	27.3%	₹61 Cr	12.9%	17.4%	13.6%	179
Bilcare LimitedBIBI	₹227 Cr	₹896 Cr	₹788 Cr	₹45 Cr	5.7%	₹-29 Cr	-7.1%	1.5%	-6%	78
Take Solutions LimitedTAKETAKE	₹187 Cr	₹187 Cr	₹85 Cr	₹-2 Cr	-3.5%	₹13 Cr	20%	18.5%	42.1%	-7
Jeevan Scientific Technology LtdJSTLJSTL	₹169 Cr	₹186 Cr	₹62 Cr	₹10 Cr	16%	₹0 Cr	1.7%	5.4%	1.7%	-109
Novelix Pharmaceuticals LtdNOVELIXNOVELIX	₹167 Cr	₹167 Cr	₹9 Cr	₹-3 Cr	-29.9%	₹-2 Cr	-23.6%	-28.1%	-28.5%	57
Globalspace Technologies LtdGSTLGSTL	₹103 Cr	—	₹25 Cr	₹11 Cr	5.9%	₹7 Cr	-1.4%	—	—	—
Adeshwar Meditex LtdADESHWARADESHWAR	₹23 Cr	—	₹56 Cr	₹3 Cr	4.9%	₹1 Cr	2.3%	—	—	—
Vanta Bioscience LtdVANTABIOVANTABIO	₹15 Cr	—	₹2 Cr	₹1 Cr	56.6%	₹0 Cr	6%	—	—	—

Date	Category	Subject	Filing
30 Sept 2026, 11:39 am	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
16 Sept 2026, 3:47 pm	Company Update Allotment of ESOP / ESPS	Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS	PDF
8 Sept 2026, 6:23 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	PDF
2 Sept 2026, 7:06 pm	Company Update Credit Rating	Announcement under Regulation 30 (LODR)-Credit Rating	PDF
1 Sept 2026, 1:08 pm	Company Update General	Clarification Regarding Increase In Volume Of Our Securities Across Exchanges.	PDF
1 Sept 2026, 12:33 pm	Company Update Clarification	Clarification sought from Vimta Labs Ltd	—
29 Aug 2026, 10:22 am	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	PDF
29 Aug 2026, 10:17 am	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	PDF

Vimta Labs Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

17

1

1

Announcements

17

1

1

Not in the F&O segment

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Compounded sales growth

Compounded profit growth

Return on equity

Vimta Labs Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

Dividends17

Board meetings1

Bonus issues1

Announcements

Dividends17

Board meetings1

Bonus issues1

Ratio timeline

Not in the F&O segment

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

17

1

1

17

1

1